Clinical Trials Logo

Microscopic Polyangiitis clinical trials

View clinical trials related to Microscopic Polyangiitis.

Filter by:

NCT ID: NCT00307645 Terminated - Clinical trials for Renal Limited Vasculitis

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis

Start date: May 2003
Phase: Phase 3
Study type: Interventional

The aim of IMPROVE is to define the optimal maintenance therapy for ANCA-associated vasculitides (AASV) by comparing the AZA (standard regimen) with MMF in terms of efficacy, i.e. in preventing relapses. HYPOTHESIS : MMF might be more effective than azathioprine as maintenance drug in AASV patients, reducing by 50% relapse rate, with a same frequency of adverse effects

NCT ID: NCT00307593 Completed - Clinical trials for Microscopic Polyangiitis

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

Start date: May 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.

NCT ID: NCT00104299 Completed - Vasculitis Clinical Trials

Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis

RAVE
Start date: January 2005
Phase: Phase 2/Phase 3
Study type: Interventional

Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.

NCT ID: NCT00103792 Recruiting - Vasculitis Clinical Trials

Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)

Start date: December 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of a new drug, mycophenolate mofetil, for the treatment of relapses of ANCA-associated vasculitis (Wegener's granulomatosis or microscopic polyangiitis). Therefore, we compare the standard therapy with cyclophosphamide to mycophenolate mofetil. The investigators expect mycophenolate mofetil to be less toxic and almost equally effective as cyclophosphamide.